Rectal cancer

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson, Yi Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Marwan G. Fakih, Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Kirk A. Ludwig, Edward W. Martin, Sujata Rao, Leonard Saltz, David Shibata, John M. SkibberAlan P. Venook

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, RT oncology, and radiology, is necessary when treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important, with a goal of evaluating at least 12 nodes when possible. Patients with T1 or T2 lesions that are node-negative on endorectal ultrasound and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for most patients with suspected or proven T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended, although upfront surgery is an option for some of these patients, particularly those with a medical contraindication to chemoRT. Patients with recurrent localized disease should be considered for resection with or without RT. Patients with metastatic disease in the liver or lung should be considered for surgical resection if they are candidates for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered for initial therapy in patients with synchronous or metachronous resectable metastatic disease (neoadjuvant) or when a response to chemotherapy can convert a patient from an unresectable to resectable state. Another option for these patients is initial treatment with chemoRT. Resection should be followed by adjuvant therapy based on prior therapy. The recommended posttreatment surveillance program for patients with rectal cancer includes serial CEA determinations; periodic chest, abdominal, and pelvic CT scans; and periodic evaluations using colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at initiation of therapy include preplanned strategies for altering therapy in the presence and absence of disease progression and plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy for advanced or metastatic disease includes bevacizumab plus FOLFOX, FOLFIRI, capecitabine, or 5-FU/LV. For patients with progressive disease who have received a 5-FU-based regimen or capecitabine as initial therapy, treatment options include chemotherapy consisting of FOLFIRI, CapeOX, FOLFOX, or irinotecan alone or, in the case of irinotecan and FOLFIRI, in combination with cetuximab. Monotherapy with either cetuximab or panitumumab is also an option after first or second progression. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

Original languageEnglish (US)
Pages (from-to)940-981
Number of pages42
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number9
StatePublished - Oct 2007

Fingerprint

Rectal Neoplasms
irinotecan
Therapeutics
Drug Therapy
Fluorouracil
Proctoscopy
Continuity of Patient Care
Medical Oncology
Gastroenterology
Colonoscopy
Adjuvant Chemotherapy
Radiology
Lung Diseases
Disease Progression
Liver Diseases
Thorax
Lymph Nodes

Keywords

  • Adjuvant chemotherapy
  • Adjuvant radiotherapy
  • Colorectal surgery
  • Fluorouracil
  • Irinotecan
  • NCCN Clinical Practice Guidelines
  • Neoplasm recurrence
  • Neoplasm staging
  • Oxaliplatin
  • Rectal neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Engstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y. J., Choti, M. A., Cooper, H. S., ... Venook, A. P. (2007). Rectal cancer. JNCCN Journal of the National Comprehensive Cancer Network, 5(9), 940-981.

Rectal cancer. / Engstrom, Paul F.; Arnoletti, Juan Pablo; Benson, Al B.; Chen, Yi Jen; Choti, Michael A.; Cooper, Harry S.; Dilawari, Raza A.; Early, Dayna S.; Fakih, Marwan G.; Fuchs, Charles; Grem, Jean L.; Kiel, Krystyna; Knol, James A.; Leong, Lucille A.; Ludwig, Kirk A.; Martin, Edward W.; Rao, Sujata; Saltz, Leonard; Shibata, David; Skibber, John M.; Venook, Alan P.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 5, No. 9, 10.2007, p. 940-981.

Research output: Contribution to journalArticle

Engstrom, PF, Arnoletti, JP, Benson, AB, Chen, YJ, Choti, MA, Cooper, HS, Dilawari, RA, Early, DS, Fakih, MG, Fuchs, C, Grem, JL, Kiel, K, Knol, JA, Leong, LA, Ludwig, KA, Martin, EW, Rao, S, Saltz, L, Shibata, D, Skibber, JM & Venook, AP 2007, 'Rectal cancer', JNCCN Journal of the National Comprehensive Cancer Network, vol. 5, no. 9, pp. 940-981.
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS et al. Rectal cancer. JNCCN Journal of the National Comprehensive Cancer Network. 2007 Oct;5(9):940-981.
Engstrom, Paul F. ; Arnoletti, Juan Pablo ; Benson, Al B. ; Chen, Yi Jen ; Choti, Michael A. ; Cooper, Harry S. ; Dilawari, Raza A. ; Early, Dayna S. ; Fakih, Marwan G. ; Fuchs, Charles ; Grem, Jean L. ; Kiel, Krystyna ; Knol, James A. ; Leong, Lucille A. ; Ludwig, Kirk A. ; Martin, Edward W. ; Rao, Sujata ; Saltz, Leonard ; Shibata, David ; Skibber, John M. ; Venook, Alan P. / Rectal cancer. In: JNCCN Journal of the National Comprehensive Cancer Network. 2007 ; Vol. 5, No. 9. pp. 940-981.
@article{860a2103ce2a45328443dcc9f28424e4,
title = "Rectal cancer",
abstract = "The panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, RT oncology, and radiology, is necessary when treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important, with a goal of evaluating at least 12 nodes when possible. Patients with T1 or T2 lesions that are node-negative on endorectal ultrasound and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for most patients with suspected or proven T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended, although upfront surgery is an option for some of these patients, particularly those with a medical contraindication to chemoRT. Patients with recurrent localized disease should be considered for resection with or without RT. Patients with metastatic disease in the liver or lung should be considered for surgical resection if they are candidates for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered for initial therapy in patients with synchronous or metachronous resectable metastatic disease (neoadjuvant) or when a response to chemotherapy can convert a patient from an unresectable to resectable state. Another option for these patients is initial treatment with chemoRT. Resection should be followed by adjuvant therapy based on prior therapy. The recommended posttreatment surveillance program for patients with rectal cancer includes serial CEA determinations; periodic chest, abdominal, and pelvic CT scans; and periodic evaluations using colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at initiation of therapy include preplanned strategies for altering therapy in the presence and absence of disease progression and plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy for advanced or metastatic disease includes bevacizumab plus FOLFOX, FOLFIRI, capecitabine, or 5-FU/LV. For patients with progressive disease who have received a 5-FU-based regimen or capecitabine as initial therapy, treatment options include chemotherapy consisting of FOLFIRI, CapeOX, FOLFOX, or irinotecan alone or, in the case of irinotecan and FOLFIRI, in combination with cetuximab. Monotherapy with either cetuximab or panitumumab is also an option after first or second progression. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.",
keywords = "Adjuvant chemotherapy, Adjuvant radiotherapy, Colorectal surgery, Fluorouracil, Irinotecan, NCCN Clinical Practice Guidelines, Neoplasm recurrence, Neoplasm staging, Oxaliplatin, Rectal neoplasms",
author = "Engstrom, {Paul F.} and Arnoletti, {Juan Pablo} and Benson, {Al B.} and Chen, {Yi Jen} and Choti, {Michael A.} and Cooper, {Harry S.} and Dilawari, {Raza A.} and Early, {Dayna S.} and Fakih, {Marwan G.} and Charles Fuchs and Grem, {Jean L.} and Krystyna Kiel and Knol, {James A.} and Leong, {Lucille A.} and Ludwig, {Kirk A.} and Martin, {Edward W.} and Sujata Rao and Leonard Saltz and David Shibata and Skibber, {John M.} and Venook, {Alan P.}",
year = "2007",
month = "10",
language = "English (US)",
volume = "5",
pages = "940--981",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Rectal cancer

AU - Engstrom, Paul F.

AU - Arnoletti, Juan Pablo

AU - Benson, Al B.

AU - Chen, Yi Jen

AU - Choti, Michael A.

AU - Cooper, Harry S.

AU - Dilawari, Raza A.

AU - Early, Dayna S.

AU - Fakih, Marwan G.

AU - Fuchs, Charles

AU - Grem, Jean L.

AU - Kiel, Krystyna

AU - Knol, James A.

AU - Leong, Lucille A.

AU - Ludwig, Kirk A.

AU - Martin, Edward W.

AU - Rao, Sujata

AU - Saltz, Leonard

AU - Shibata, David

AU - Skibber, John M.

AU - Venook, Alan P.

PY - 2007/10

Y1 - 2007/10

N2 - The panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, RT oncology, and radiology, is necessary when treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important, with a goal of evaluating at least 12 nodes when possible. Patients with T1 or T2 lesions that are node-negative on endorectal ultrasound and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for most patients with suspected or proven T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended, although upfront surgery is an option for some of these patients, particularly those with a medical contraindication to chemoRT. Patients with recurrent localized disease should be considered for resection with or without RT. Patients with metastatic disease in the liver or lung should be considered for surgical resection if they are candidates for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered for initial therapy in patients with synchronous or metachronous resectable metastatic disease (neoadjuvant) or when a response to chemotherapy can convert a patient from an unresectable to resectable state. Another option for these patients is initial treatment with chemoRT. Resection should be followed by adjuvant therapy based on prior therapy. The recommended posttreatment surveillance program for patients with rectal cancer includes serial CEA determinations; periodic chest, abdominal, and pelvic CT scans; and periodic evaluations using colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at initiation of therapy include preplanned strategies for altering therapy in the presence and absence of disease progression and plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy for advanced or metastatic disease includes bevacizumab plus FOLFOX, FOLFIRI, capecitabine, or 5-FU/LV. For patients with progressive disease who have received a 5-FU-based regimen or capecitabine as initial therapy, treatment options include chemotherapy consisting of FOLFIRI, CapeOX, FOLFOX, or irinotecan alone or, in the case of irinotecan and FOLFIRI, in combination with cetuximab. Monotherapy with either cetuximab or panitumumab is also an option after first or second progression. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

AB - The panel believes that a multidisciplinary approach, including representation from gastroenterology, medical oncology, surgical oncology, RT oncology, and radiology, is necessary when treating patients with rectal cancer. Adequate pathologic assessment of the resected lymph nodes is important, with a goal of evaluating at least 12 nodes when possible. Patients with T1 or T2 lesions that are node-negative on endorectal ultrasound and who meet carefully defined criteria can be managed with a transanal excision. A transabdominal resection is appropriate for all other rectal lesions. Preoperative chemoRT is preferred for most patients with suspected or proven T3/T4 disease and/or regional node involvement, and adjuvant chemotherapy is recommended, although upfront surgery is an option for some of these patients, particularly those with a medical contraindication to chemoRT. Patients with recurrent localized disease should be considered for resection with or without RT. Patients with metastatic disease in the liver or lung should be considered for surgical resection if they are candidates for surgery and if complete resection (RO) or ablation can be achieved. Preoperative chemotherapy can be considered for initial therapy in patients with synchronous or metachronous resectable metastatic disease (neoadjuvant) or when a response to chemotherapy can convert a patient from an unresectable to resectable state. Another option for these patients is initial treatment with chemoRT. Resection should be followed by adjuvant therapy based on prior therapy. The recommended posttreatment surveillance program for patients with rectal cancer includes serial CEA determinations; periodic chest, abdominal, and pelvic CT scans; and periodic evaluations using colonoscopy and proctoscopy. Recommendations for patients with previously untreated disseminated metastatic disease represent a continuum of care in which lines of treatment are blurred rather than discrete. Principles to consider at initiation of therapy include preplanned strategies for altering therapy in the presence and absence of disease progression and plans for adjusting therapy for patients who experience certain toxicities. Recommended initial therapy for advanced or metastatic disease includes bevacizumab plus FOLFOX, FOLFIRI, capecitabine, or 5-FU/LV. For patients with progressive disease who have received a 5-FU-based regimen or capecitabine as initial therapy, treatment options include chemotherapy consisting of FOLFIRI, CapeOX, FOLFOX, or irinotecan alone or, in the case of irinotecan and FOLFIRI, in combination with cetuximab. Monotherapy with either cetuximab or panitumumab is also an option after first or second progression. The panel endorses the concept that treating patients in a clinical trial has priority over standard or accepted therapy.

KW - Adjuvant chemotherapy

KW - Adjuvant radiotherapy

KW - Colorectal surgery

KW - Fluorouracil

KW - Irinotecan

KW - NCCN Clinical Practice Guidelines

KW - Neoplasm recurrence

KW - Neoplasm staging

KW - Oxaliplatin

KW - Rectal neoplasms

UR - http://www.scopus.com/inward/record.url?scp=35948992985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35948992985&partnerID=8YFLogxK

M3 - Article

C2 - 17977503

AN - SCOPUS:35948992985

VL - 5

SP - 940

EP - 981

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 9

ER -